我们真的需要基于奥密克戎 Spike 的更新版 COVID-19 疫苗吗？证据和研发管线。
Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline.
机构信息
North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy.
National Institute for Infectious Diseases "L. Spallanzani", 00161 Roma, Italy.
出版信息
Viruses. 2022 Nov 10;14(11):2488. doi: 10.3390/v14112488.
Abstract
The wild-type SARS-CoV-2 Spike-based vaccines authorized so far have reduced COVID-19 severity, but periodic boosts are required to counteract the decline in immunity. An accelerated rate of immune escape to vaccine-elicited immunity has been associated with Spike protein antigenic shifts, as seen in the Omicron variant of concern and its sublineages, demanding the development of Omicron Spike-based vaccines. Herein, we review the evidence in animal models and topline results from ongoing clinical trials with such updated vaccines, discussing the pros and cons for their deployment.
摘要
迄今为止，获得授权的基于野生型 SARS-CoV-2 刺突蛋白的疫苗已经降低了 COVID-19 的严重程度，但需要定期加强针来对抗免疫的下降。正如在关注的奥密克戎变体及其亚谱系中所见，对疫苗诱导的免疫的免疫逃逸速度加快与刺突蛋白抗原转变有关，因此需要开发基于奥密克戎刺突蛋白的疫苗。在此，我们综述了这些更新的疫苗在动物模型中的证据和正在进行的临床试验的主要结果，讨论了它们部署的优缺点。
相似文献
1
Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline.
Viruses. 2022 Nov 10;14(11):2488. doi: 10.3390/v14112488.
2
Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines.
J Med Virol. 2022 Dec;94(12):5678-5690. doi: 10.1002/jmv.28032. Epub 2022 Aug 6.
3
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era.
Expert Rev Vaccines. 2023 Jan-Dec;22(1):650-661. doi: 10.1080/14760584.2023.2232851.
4
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection.
Emerg Microbes Infect. 2022 Dec;11(1):1828-1832. doi: 10.1080/22221751.2022.2099305.
5
A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
J Med Virol. 2022 Sep;94(9):4287-4293. doi: 10.1002/jmv.27885. Epub 2022 Jun 2.
6
Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine.
Viruses. 2022 Sep 13;14(9):2023. doi: 10.3390/v14092023.
7
Antibody evasion properties of SARS-CoV-2 Omicron sublineages.
Nature. 2022 Apr;604(7906):553-556. doi: 10.1038/s41586-022-04594-4. Epub 2022 Mar 3.
8
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633.
9
Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.
Cell Rep. 2023 Aug 29;42(8):112888. doi: 10.1016/j.celrep.2023.112888. Epub 2023 Jul 31.
10
Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
J Immunol Res. 2022 Aug 31;2022:4813199. doi: 10.1155/2022/4813199. eCollection 2022.
引用本文的文献
1
Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases.
Cell Commun Signal. 2023 May 15;21(1):110. doi: 10.1186/s12964-023-01104-5.
2
Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge.
Int J Mol Sci. 2023 Jan 23;24(3):2264. doi: 10.3390/ijms24032264.
3
From Co-Administration to Co-Formulation: The Race for New Vaccines against COVID-19 and Other Respiratory Viruses.
Vaccines (Basel). 2023 Jan 2;11(1):109. doi: 10.3390/vaccines11010109.
本文引用的文献
1
Long-term humoral response following Delta and Omicron BA.1 co-infection.
NPJ Vaccines. 2023 Apr 20;8(1):57. doi: 10.1038/s41541-023-00652-8.
2
Predicting the efficacy of variant-modified COVID-19 vaccine boosters.
Nat Med. 2023 Mar;29(3):574-578. doi: 10.1038/s41591-023-02228-4. Epub 2023 Mar 2.
3
Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1.
N Engl J Med. 2023 Feb 16;388(7):662-664. doi: 10.1056/NEJMc2214314. Epub 2023 Jan 18.
4
Antibody Response to Omicron BA.4-BA.5 Bivalent Booster.
N Engl J Med. 2023 Feb 9;388(6):567-569. doi: 10.1056/NEJMc2213907. Epub 2023 Jan 11.
5
Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters.
N Engl J Med. 2023 Feb 9;388(6):565-567. doi: 10.1056/NEJMc2213948. Epub 2023 Jan 11.
6
Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster.
N Engl J Med. 2023 Jan 12;388(2):183-185. doi: 10.1056/NEJMc2214293. Epub 2022 Dec 21.
7
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.
Nat Med. 2023 Feb;29(2):344-347. doi: 10.1038/s41591-022-02162-x. Epub 2022 Dec 6.
8
Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster.
iScience. 2022 Nov 18;25(11):105465. doi: 10.1016/j.isci.2022.105465. Epub 2022 Oct 31.
9
Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters.
Nat Commun. 2022 Nov 4;13(1):6644. doi: 10.1038/s41467-022-34439-7.
10
Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5.
Cell Discov. 2022 Oct 11;8(1):108. doi: 10.1038/s41421-022-00473-4.
Zotero 插件